

**Simparica Trio**

*Small, medium, and large dog chewable tablets*

**Mode of Action**

SIMPARICA TRIO contains three active pharmaceutical ingredients, sarolaner, moxidectin, and pyrantel pamoate. Sarolaner is an acaricide and insecticide belonging to the benzimidazole class; moxidectin is an endectocide in the macrocyclic lactone class; and pyrantel pamoate is a nematocide in the benzimidazole class.

**Description**

Simparica Trio is a tebuthiamine prodrug of tebuthiamine methiodide which is a fermentation product of Streptomyces cyanescens subsp. cyanescens. Moxidectin is a synthetic endectocide belonging to the macrocyclic lactone class (12-deoxynojirimycin). Pyrantel belongs to a family classified chemically as benzimidazoles.

**Indications**

Simparica Trio is indicated for the prevention of heartworm disease caused by Dirofilaria immitis in adult and immature adult heartworms in dogs. It is also indicated for the treatment and prevention of flea infestations and the treatment and control of cutaneous localizations with demodectic mange in dogs and flea-borne tick infestations in dogs and cats.

**Usage**

Simparica Trio should be administered orally at 1 and 3 mg per kg of body weight (1.4 mg per lbs of body weight) at monthly intervals year-round or at least within one month of initial dosing, if your veterinarian directed.

**Treatment with SIMPARICA TRIO**

Treatment with SIMPARICA TRIO may begin at any time of the year. SIMPARICA TRIO should be administered monthly year-round or at least within one month of initial dosing, if your veterinarian directed.

**Contraindications**

There are no known contraindications for the use of SIMPARICA TRIO.

**Warnings**

Not for use in humans. Keep this and all other drugs out of reach of children.

**Precautions**

Simparica Trio is a secure location out of reach of children and other pets to prevent accidental ingestion.

**Sarolaner**

Sarolaner is a member of the isoazoline class of guanidines and the chemical name is 1-(1-BZ)-1,2-dihydro-3-ethyl-3-oxo-2-(phenylimino)-1H-pyrazolo[3,4-b]pyridine-6-carbonitrile.

**Moxidectin**

Moxidectin is an endectocide in the macrocyclic lactone class. It is a member of the macrocyclic lactone class of compounds, with a specific mode of action that affects the sodium channel, which causes paralysis and death or expulsion of the organism.

**Fleas and Ticks**

Fleas and ticks are major pests of pets and their owners. Fleas can cause severe discomfort in dogs and can transmit diseases such as bartonellosis and ehrlichiosis. Ticks can carry a variety of diseases, including Lyme disease and Rocky Mountain spotted fever. SIMPARICA TRIO demonstrated 100% effectiveness against fleas within 2 hours of oral administration. After weekly re-infestations, SIMPARICA TRIO reduced the number of live fleas by 96.8% within 12 hours of re-infestation for 24 days. In a well-controlled 10-week field study conducted in dogs with existing tick infestations, the effectiveness of SIMPARICA TRIO against ticks on Day 30 and 60 (80%) was 98% and 97%, respectively, compared with a placebo. SIMPARICA TRIO demonstrated 100% effectiveness against adult ticks with 24 hours following treatment and maintained 99% effectiveness against weekly re-infestation for 24 days.

**Heartworm Disease**

Heartworm disease is a parasitic infection of dogs. Heartworm disease is caused by Dirofilaria immitis, which is transmitted by mosquitoes. Dogs and cats can become infected by ingesting infected mosquitoes or by being bitten by infected mosquitoes. Heartworm disease is a serious and potentially fatal disease in dogs. In a well-controlled 120-day US field study conducted in dogs with existing tick infestations, the effectiveness of SIMPARICA TRIO against adults with ≥90% effectiveness 48 hours post-administration and maintained 99% effectiveness against weekly re-infestations for 24 days. In a well-controlled 120-day US field study conducted in dogs with existing tick infestations, the effectiveness of SIMPARICA TRIO against adults with ≥90% effectiveness 48 hours post-administration and maintained 99% effectiveness against weekly re-infestations for 24 days.

**Intestinal Worms**

Intestinal worms are parasites that can affect pets of all sizes and breeds. SIMPARICA TRIO is indicated for the treatment and control of a variety of intestinal worms in dogs. SIMPARICA TRIO demonstrated 98% effectiveness against hookworms (immature adult and adult), 99.4% effectiveness 72 hours after re-infestation for at least 90% effectiveness 48 hours after re-infestation in dogs with hookworms (immature adult and adult) and adult Anisakis nematodes. In a well-controlled 10-day field study conducted in dogs with existing infestations, SIMPARICA TRIO demonstrated 98% effectiveness against hookworms (immature adult and adult) and adult Ancylostoma caninum, and 99.6% effectiveness against adult Ancylostoma braziliense and Uncinaria stenocephala.

**Tick Treatment and Control**

SIMPARICA TRIO demonstrated 100% effectiveness against adult ticks with 24 hours following treatment and maintained 99% effectiveness against weekly re-infestation for 24 days. In a well-controlled 16-week field study conducted in dogs with existing tick infestations, the effectiveness of SIMPARICA TRIO against ticks on Day 30 and 60 (80%) was 98% and 97%, respectively, compared with a placebo. SIMPARICA TRIO demonstrated 100% effectiveness against adult ticks with 24 hours following treatment and maintained 99% effectiveness against weekly re-infestation for 24 days.

**Interbreed Sensitivity**

In a small group of Ivermectin-sensitive Collie safety study, SIMPARICA TRIO was administered orally at 1 and 3 mg the maximum labeled dose at 28 days intervals for 14 days in 3 collie dogs. All dogs were completely recovered by the end of the study. SIMPARICA TRIO was administered orally at 1 and 3 mg the maximum labeled dose at 28 days intervals for 14 days in 3 collie dogs. All dogs were completely recovered by the end of the study. SIMPARICA TRIO was administered orally at 1 and 3 mg the maximum labeled dose at 28 days intervals for 14 days in 3 collie dogs. All dogs were completely recovered by the end of the study. SIMPARICA TRIO was administered orally at 1 and 3 mg the maximum labeled dose at 28 days intervals for 14 days in 3 collie dogs. All dogs were completely recovered by the end of the study.